重庆市 248 例新型冠状病毒肺炎患者临床特征及预后分析.

Objective To explore and analyze the clinical characteristics and prognosis of 248 patients with novel coronavirus pneumonia (COVID-19) in Chongqing, so as to provide reference for clinical diagnosis and treatment of COVID-19. Methods The clinical data of 248 patients with COV ID-19 admitted to the hospital from January 21 to March 11, 2020 were retrospectively analyzed, including 195 patients in the non-severe group (mild type/normal type) and the severe group (severe type/critical type). Type) 53 cases. Comparing the general conditions, clinical manifestations, laboratory test results and prognosis of the two groups of patients, the average age of 248 patients was (47.69±15.59) years old. Adults accounted for 97.6% (242/248), men were slightly more than women (54.0% (134/248), 46.0% (114/248), respectively), hospitalization time was 14.00 (12.00, 22,000 days. The fatality rate was 16% ( 4/248), the fatality rate of patients in the severe group was 7.5% (4/53). After the cured patients were discharged from the hospital, 4 patients in the non-critical group were followed up for reimpedance, and there was no evidence of infecting others. The age of the severe group patients, as well as diabetes and chronic obstruction The proportions of pulmonary disease, coronary heart disease, malignant tumors, cough, sputum, shortness of breath, dyspnea, and fatigue are all significantly higher than those of the non-severe group. The counts of lymphocytes, monocytes, lymphocytes, total T lymphocytes, Helper/inducible T lymphocytes, inhibitory/cytotoxic T lymphocytes, B lymphocytes, and natural killer cells are significantly lower than the non-severe group, neutrophils, urea nitrogen, direct bilirubin, aspartate aminotransferase, prothrombin time, Partially activated prothrombin time, D-dimer. C-reactive protein, procalcitonin, and interleukin-6 were significantly higher than those in the non-critical group, and the differences were statistically significant (P<0.05). Conclusions Elderly Patients with diabetes mellitus, chronic obstructive pulmonary disease, coronary heart disease, malignant tumors and other diseases are more likely to progress to severe cases. Clinical medical advancement combines patient symptoms and related laboratory test results to identify critically ill patients early and admit them to the intensive care unit for enhanced monitoring and treatment. Reduce the fatality rate of COVID 19 patients. [ABSTRACT FROM AUTHOR]